Correction to: Molecular Psychiatry advance online publication, 8 December 2015; doi:10.1038/mp.2015.178
Following publication of this paper, the authors noticed that Figures 5a and b contained the same image. In addition, there was a typo in Table 3 at #703. The correct figure and table appear here.
(a–d) Efficacy outcomes in means over time.
Additional information
The online version of the original article can be found at 10.1038/mp.2015.178
PowerPoint slides
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Fava, M., Johe, K., Ereshefsky, L. et al. Erratum: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry 21, 1483–1484 (2016). https://doi.org/10.1038/mp.2016.140
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2016.140
This article is cited by
-
Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis
Translational Psychiatry (2021)
-
Neuroprotective efficacy of P7C3 compounds in primate hippocampus
Translational Psychiatry (2018)
-
Experimental medication treatment approaches for depression
Translational Psychiatry (2017)
